BRPI0417943A - antagonistas de receptor de crf e métodos relacionados para essa finalidade - Google Patents

antagonistas de receptor de crf e métodos relacionados para essa finalidade

Info

Publication number
BRPI0417943A
BRPI0417943A BRPI0417943-9A BRPI0417943A BRPI0417943A BR PI0417943 A BRPI0417943 A BR PI0417943A BR PI0417943 A BRPI0417943 A BR PI0417943A BR PI0417943 A BRPI0417943 A BR PI0417943A
Authority
BR
Brazil
Prior art keywords
receptor antagonists
crf receptor
related methods
crf
disorders
Prior art date
Application number
BRPI0417943-9A
Other languages
English (en)
Inventor
Zhiyong Luo
Deborah H Slee
John Edward Tellew
John P Williams
Xiaohu Zhang
Original Assignee
Sb Pharmco Inc
Neurocrine Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sb Pharmco Inc, Neurocrine Biosciences Inc filed Critical Sb Pharmco Inc
Publication of BRPI0417943A publication Critical patent/BRPI0417943A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

"ANTAGONISTAS DE RECEPTOR DO CRF E MéTODOS RELACIONADOS PARA ESSA FINALIDADE". Antagonistas de receptor do CRF são revelados os quais possuem utilidade no tratamento de uma variedade de distúrbios, incluindo o tratamento de distúrbios que manifestam hipersecreção do CRF em animais de sangue quente, tais como derrame. Os antagonistas de receptor do CRF dessa invenção possuem a estrutura seguinte (I), incluindo seus estereoisómeros, prodrogas e seus sais farmaceuticamente aceitáveis, onde R1, R2, R3, Y, Ar, e Het são como aqui definidos. Composições contendo um antagonista de receptor do CRF combinação com um veículo farmaceuticamente aceitável são também reveladas, bem como métodos para sua utilização.
BRPI0417943-9A 2003-12-22 2004-12-20 antagonistas de receptor de crf e métodos relacionados para essa finalidade BRPI0417943A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US53203103P 2003-12-22 2003-12-22
PCT/IB2004/004234 WO2005063755A1 (en) 2003-12-22 2004-12-20 Crf receptor antagonists and methods relating thereto

Publications (1)

Publication Number Publication Date
BRPI0417943A true BRPI0417943A (pt) 2007-04-17

Family

ID=34738733

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0417943-9A BRPI0417943A (pt) 2003-12-22 2004-12-20 antagonistas de receptor de crf e métodos relacionados para essa finalidade

Country Status (19)

Country Link
US (1) US7737154B2 (pt)
EP (1) EP1697374B1 (pt)
JP (1) JP4926720B2 (pt)
KR (1) KR20070009537A (pt)
CN (1) CN1938309B (pt)
AR (1) AR046967A1 (pt)
AU (1) AU2004309168B2 (pt)
BR (1) BRPI0417943A (pt)
CA (1) CA2550948A1 (pt)
IL (1) IL176350A0 (pt)
IS (1) IS8526A (pt)
MA (1) MA29984B1 (pt)
MY (1) MY143499A (pt)
NO (1) NO20063230L (pt)
NZ (1) NZ547990A (pt)
RU (1) RU2394035C2 (pt)
TW (1) TW200530242A (pt)
WO (1) WO2005063755A1 (pt)
ZA (1) ZA200604574B (pt)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0308208D0 (en) 2003-04-09 2003-05-14 Glaxo Group Ltd Chemical compounds
US8815599B2 (en) 2004-06-01 2014-08-26 Pronai Therapeutics, Inc. Methods and compositions for the inhibition of gene expression
US7652035B2 (en) * 2004-10-19 2010-01-26 Neurocrine Bioscience, Inc. CRF receptor antagonists and methods relating thereto
GB0519957D0 (en) 2005-09-30 2005-11-09 Sb Pharmco Inc Chemical compound
US8088779B2 (en) * 2005-09-30 2012-01-03 Smithkline Beecham (Cork) Limited Pyrazolo [1,5-alpha] pyrimidinyl derivatives useful as corticotropin-releasing factor (CRF) receptor antagonists
KR101088239B1 (ko) 2006-09-20 2011-11-30 일라이 릴리 앤드 캄파니 Ｃｒｆ１ 수용체 길항제로서의 티아졸 피라졸로피리미딘
MX2009003098A (es) 2006-09-20 2009-04-01 Lilly Co Eli Compuestos de tiofen pirazolopirimidina.
KR100854679B1 (ko) * 2007-02-03 2008-08-27 김기형 심플 서비스 로케이션 프로토콜 네트워크 시스템 및 이를구성하는 에이전트.
EP2282998B1 (en) * 2008-04-21 2014-09-10 Albemarle Corporation Processes for producing n-alkylpyrazole
EP2531490B1 (en) * 2010-02-02 2014-10-15 Novartis AG Cyclohexyl amide derivatives as crf receptor antagonists
WO2014060381A1 (de) 2012-10-18 2014-04-24 Bayer Cropscience Ag Heterocyclische verbindungen als schädlingsbekämpfungsmittel
US20150284380A1 (en) 2012-10-31 2015-10-08 Bayer Cropscience Ag Novel heterocyclic compounds as pest control agents
JP6359175B2 (ja) * 2014-04-10 2018-07-18 フーベイ バイオ−ファーマシューティカル インダストリアル テクノロジカル インスティテュート インコーポレイテッド ＰＡＲＰ阻害剤としての４Ｈ‐ピラゾロ［１，５‐α］ベンゾイミダゾール化合物のアナログ
BR112020002967A2 (pt) 2017-08-14 2020-08-11 Spruce Biosciences, Inc. antagonistas de receptor de fator de liberação de corticotropina
MX2020011344A (es) 2018-04-27 2021-02-09 Spruce Biosciences Inc Métodos para tratar tumores en reposo suprarrenales testiculares y de ovarios.
CA3187362A1 (en) 2020-07-27 2022-02-03 John Thomas Feutrill Compounds
JP2023537598A (ja) 2020-08-12 2023-09-04 スプルース バイオサイエンシーズ，インク． 多嚢胞性卵巣症候群を処置するための方法および組成物
US11708372B2 (en) 2021-11-19 2023-07-25 Spruce Biosciences, Inc. Crystalline composition of tildacerfont and methods of use and preparation thereof

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2168237T3 (es) * 1996-02-07 2007-04-01 Neurocrine Biosciences, Inc. Pirazolopirimidinas como antagonistas de receptores de crf.
US6313124B1 (en) 1997-07-23 2001-11-06 Dupont Pharmaceuticals Company Tetrazine bicyclic compounds
US6060478A (en) * 1996-07-24 2000-05-09 Dupont Pharmaceuticals Azolo triazines and pyrimidines
AU747708B2 (en) 1996-07-24 2002-05-23 Du Pont Pharmaceuticals Company Azolo triazines and pyrimidines
PL332040A1 (en) 1996-08-28 1999-08-16 Pfizer Substitution 6,5-heterobicyclic derivatives
CA2291709A1 (en) * 1997-05-30 1998-12-03 Merck & Co., Inc. Novel angiogenesis inhibitors
IL137019A0 (en) * 1998-01-28 2001-06-14 Du Pont Pharm Co Azolo triazines and pyrimidines
AU4203500A (en) 1999-04-06 2000-10-23 Du Pont Pharmaceuticals Company Pyrazolopyrimidines as crf antagonists
YU23602A (sh) * 1999-09-30 2004-09-03 Neurogen Corporation Amino supstituisani pirazolo /1,5/a/-1,5-pirimidini i pirazolo /1,5-a/-1,3,5-triazini
IL139197A0 (en) * 1999-10-29 2001-11-25 Pfizer Prod Inc Use of corticotropin releasing factor antagonists and related compositions
CA2446514A1 (en) * 2001-04-30 2002-11-07 Glaxo Group Limited Fused pyrimidines as antagonists of the corticotropin releasing factor (crf)
ATE397609T1 (de) * 2001-06-12 2008-06-15 Glaxo Group Ltd Corticotropinfreisetzungsfaktor antagonisten
GB0117396D0 (en) * 2001-07-17 2001-09-05 Glaxo Group Ltd Chemical compounds
EP1583531B1 (en) * 2003-01-16 2007-04-18 SB Pharmco Puerto Rico Inc Heteroaryl-substituted pyrrolo[2, 3- b]pyridine derivatives as crf receptor antagonists
WO2004087707A1 (en) 2003-03-31 2004-10-14 Vernalis (Cambridge) Limited Pyrazolopyrimidine compounds and their use in medicine
US20070021429A1 (en) * 2003-04-09 2007-01-25 Yves St-Denis Condensed n-heterocyclic compounds and their use as crf receptor antagonists
GB0308208D0 (en) * 2003-04-09 2003-05-14 Glaxo Group Ltd Chemical compounds
US20070293511A1 (en) * 2003-12-22 2007-12-20 Sb Pharmco Puerto Rico Inc. And Neurocrine Biosciences, Inc., A Corporation Crf Receptor Antagonists and Methods
DE102004008807A1 (de) * 2004-02-20 2005-09-08 Bayer Cropscience Ag Pyrazolopyrimidine
US7652035B2 (en) * 2004-10-19 2010-01-26 Neurocrine Bioscience, Inc. CRF receptor antagonists and methods relating thereto
GB0519957D0 (en) * 2005-09-30 2005-11-09 Sb Pharmco Inc Chemical compound
US8088779B2 (en) * 2005-09-30 2012-01-03 Smithkline Beecham (Cork) Limited Pyrazolo [1,5-alpha] pyrimidinyl derivatives useful as corticotropin-releasing factor (CRF) receptor antagonists

Also Published As

Publication number Publication date
EP1697374B1 (en) 2012-08-29
AR046967A1 (es) 2006-01-04
CA2550948A1 (en) 2005-07-14
RU2006126675A (ru) 2008-01-27
NZ547990A (en) 2010-04-30
AU2004309168A1 (en) 2005-07-14
US20070287705A1 (en) 2007-12-13
CN1938309B (zh) 2011-11-09
NO20063230L (no) 2006-09-12
RU2394035C2 (ru) 2010-07-10
MY143499A (en) 2011-05-31
WO2005063755A1 (en) 2005-07-14
IS8526A (is) 2006-07-11
AU2004309168B2 (en) 2009-04-23
TW200530242A (en) 2005-09-16
ZA200604574B (en) 2007-11-28
MA29984B1 (fr) 2008-12-01
JP4926720B2 (ja) 2012-05-09
JP2007515472A (ja) 2007-06-14
EP1697374A1 (en) 2006-09-06
KR20070009537A (ko) 2007-01-18
US7737154B2 (en) 2010-06-15
CN1938309A (zh) 2007-03-28
IL176350A0 (en) 2006-10-05

Similar Documents

Publication Publication Date Title
DK1129091T3 (da) Antagonister for CRF-receptorer og fremgangsmåder med relation dertil
BRPI0417478A (pt) 2,6-bis-heteroaril-4-aminopirimidinas como antagonistas de receptor de adenosina
MX9605128A (es) Nuevos derivados de aminoacidos, procedimientos para su preparacion y composiciones farmaceuticas que contienen estos compuestos.
MXPA05011710A (es) Derivados de pirimidina con actividad de crf.
EA200500017A1 (ru) Новые соединения
ATE430746T1 (de) Crf-rezeptor-antagonisten und zugehörige verfahren
NO20070555L (no) Kinazolinonderivater som parp-inhibitorer
ECSP055676A (es) Piperazinas heterocíclicas sustituidas para el tratamiento de la esquizofrenia
IS8503A (is) Azatvíhringja heteróhringir sem kannabínóníð-viðtakastillar
MXPA05004188A (es) Antagonistas de cgrp elegidos, procedimiento para su preparacion, asi como su empleo como medicamentos.
CA2603830A1 (en) PYRIDINE [2,3-B] PYRAZINONES
NO20076680L (no) Utvalgte CGRP-antagonister, metoder for fremstilling av disse og deres anvendelse som medikamenter
PL1620425T3 (pl) Podstawione 3-cyjanotiofenoacetamidy jako antagoniści receptora glukagonu
DK1129096T3 (da) CRF-receptorantagonister og fremgangsmåder, der er relateret dertil
ATE359791T1 (de) Pyrimidin-2,4-dion-derivate als matrix- metalloproteinase-hemmer
EA200500899A1 (ru) Антагонисты аденозиндифосфатного рецептора тромбоцитов
NO20063230L (no) CRF receptorantagonister og fremgangsmater for fremstilling derav
BRPI0406704A (pt) Antagonistas de 5ht~7~ e agonistas inversos
MXPA04006571A (es) Derivado de pirimidina biciclica fusionada.
BR0209947A (pt) Derivados tri- e tetraaza-acenaftilen como antagonista do receptor de crf
TW200800962A (en) Selected CGRP antagonists, processes for preparing them and their use as pharmaceutical compositions
BRPI0411867A (pt) tiofenilaminoimidazolinas
DE60100811D1 (de) Crf rezeptor-antagonisten und darauf bezogene methoden
BR0308844A (pt) Derivado de pirimidina bicìclica fundida e seus sais farmaceuticamente aceitáveis que atuam como antagonistas do receptor de taquicinina, bem como, as aplicações médicas desses compostos
DE60100539D1 (en) Tosylprolin-derivate als thymidylat-synthase inhibitoren

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: SB PHARMCO PUERTO RICO INC. (US) , NEUROCRINE BIOS

Free format text: TRANSFERIDO PARTE DOS DIREITOS DE: SB PHARMCO PUERTO RICO INC.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: PARA: INT. CL. C07D 487/04; A61K 31/495; A61P 25/00

Ipc: C07D 487/04 (2011.01), A61K 31/495 (2011.01), A61P

B11E Dismissal acc. art. 34 of ipl - requirements for examination incomplete
B11T Dismissal of application maintained [chapter 11.20 patent gazette]